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Dosimetric feasibility of 4DCT-ventilation
imaging guided proton therapy for locally
advanced non-small-cell lung cancer
Qijie Huang1,2, Salma K. Jabbour1, Zhiyan Xiao1,3, Ning Yue1, Xiao Wang1, Hongbin Cao4, Yu Kuang5,
Yin Zhang1 and Ke Nie1*

Abstract
Background: The principle aim of this study is to incorporate 4DCT ventilation imaging into functional treatment
planning that preserves high-functioning lung with both double scattering and scanning beam techniques in
proton therapy.
Methods: Eight patients with locally advanced non-small-cell lung cancer were included in this study. Deformable
image registration was performed for each patient on their planning 4DCTs and the resultant displacement vector
field with Jacobian analysis was used to identify the high-, medium- and low-functional lung regions. Five plans
were designed for each patient: a regular photon IMRT vs. anatomic proton plans without consideration of functional
ventilation information using double scattering proton therapy (DSPT) and intensity modulated proton therapy (IMPT)
vs. functional proton plans with avoidance of high-functional lung using both DSPT and IMPT. Dosimetric parameters
were compared in terms of tumor coverage, plan heterogeneity, and avoidance of normal tissues.
Results: Our results showed that both DSPT and IMPT plans gave superior dose advantage to photon IMRTs in sparing
low dose regions of the total lung in terms of V5 (volume receiving 5Gy). The functional DSPT only showed marginal
benefit in sparing high-functioning lung in terms of V5 or V20 (volume receiving 20Gy) compared to anatomical plans.
Yet, the functional planning in IMPT delivery, can further reduce the low dose in high-functioning lung without degrading
the PTV dosimetric coverages, compared to anatomical proton planning. Although the doses to some critical organs might
increase during functional planning, the necessary constraints were all met.
Conclusions: Incorporating 4DCT ventilation imaging into functional proton therapy is feasible. The functional proton
plans, in intensity modulated proton delivery, are effective to further preserve high-functioning lung regions without
degrading the PTV coverage.
Keywords: 4D-CT ventilation imaging, Functional imaging guided proton therapy

Background
As confirmed by Radiation Therapy Oncology Group
(RTOG) 9311 and several other clinical trials, doseescalation is necessary and strongly associated with the
improved survival for lung cancer patient receiving
radiation treatment [1, 2]. However, tolerance of the
normal lung to radiotherapy often limits the amount of
radiotherapy that can be delivered to the primary cancer
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site. It showed that when concurrent chemotherapy was
given in Stage III disease, more than 50% of patients
developed Grade 3 or higher acute toxic effects and
10–15% of patients developed Grade 3 or higher chronic
toxic effects [2]. Mean total lung dose, volume receiving
5 Gy (V5) and volume receiving 20 Gy (V20) are
documented as being correlated with treatment-related
toxicity. For example, radiation pneumonitis (RP), the
most common complication of radiation therapy for
non-small cell lung cancer (NSCLC), is found to be
closely correlated with total lung V20. When V20 was
over 22%, 32% and 40%, the incidence of radiation
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pneumonitis within 2 years increased from 0% to 7%,
13% and 36% respectively [3].
However, the current radiation planning practice assumes a uniform distribution of pulmonary function and
homogeneous response to radiation. In fact, pulmonary
function heterogeneity is present in lung cancer patients
such as the lower lung has higher ventilation function
levels than the upper lung [4]. Yorke et al. also demonstrated that the mean dose to the lower lung was more
predictive of toxicity than that to the upper parts [5].
These findings suggested a radiation treatment strategy
for avoidance of high-functioning lung, which might
have the potential to reduce pulmonary toxicity thus to
give possibility for dose-escalation. Previous studies have
demonstrated decreasing the radiation dose to highfunctioning lung areas and directing the radiation beams
to the parts with perfusion/ventilation defects may help
to protect highly functioning lung regions and thus reduce the incidence and seriousness of radiation pneumonitis (RP) [6–12]. There are even several on-going
clinical trials as NCT02528942, NCT02308709, and
NCT02843568 to evaluate the clinical outcome that utilizing functional imaging guided photon radiation to
avoid more functional portions of the lung.
The presence of functional defects and advances in
imaging techniques have led to an interest in utilizing
functional imaging modalities such as single photon
emission computed tomography (SPECT) [13, 14],
hyperpolarized Helium or Xenon MRI [15, 16], and 4dimensional (4D) computed tomography (CT) ventilation imaging [7, 9, 17], to identify high functioning lung
for the purpose of preferential radiation sparing. Because
4D-CT imaging is increasingly a standard for lung cancer treatment, it can be implemented with little additional radiation or cost to the patients. Previous studies
have detailed the methodology of 4D-CT ventilation imaging [7, 17], the validation of the technique [18–21],
and its potential clinical uses as a functional imaging
modality [8, 10, 22, 23].
However, to our best knowledge, all previous studies
focused on the feasibility of functional imaging guided

photon treatment either using 3D-conformal radiation
therapy (CRT) or IMRT techniques. It is known that,
proton therapy has the physical properties to deliver
minimal dose beyond distal end of the Bragg peak,
which generally allows for reduced doses to organs at
risk compared to photon therapy. In this study, we take
functional imaging guided therapy one step further to
investigate the feasibility of incorporating pulmonary
function information derived from 4D-CT data into proton planning, and to compare the benefits of sparing
high-functioning lung in both functional-guided double
scatter proton therapy (DSPT) and intensity modulated
proton therapy (IMPT) for locally advanced non-smallcell lung cancer (NSCLC).

Methods
Patient selection and CT imaging data

This study was approved by the Institutional Review
Board. Ten consecutive patients (6 female) with locally
advanced non-small cell lung cancer (NSCLC) who
underwent proton treatment at our institutes were selected. Each patient had clinically-approved double scatter proton treatment (DSPT) plan and an IMRT plan
designed for insurance purpose. Patient’s plan was revisited and redesigned later with intensity modulated proton treatment (IMPT) capability. In our clinic, if the
patient breathing motion is less than 10 mm measured
from CT0 (end-of-inspiration) to CT50 (end-of-expiration), then the patient can be recommended for DSPT
treatment. While the clinic criterion in screening patients suitable for IMPT is tighter compared to DSPT
treatment, patients breathing motion should be limited
to 5–7 mm from CT0 (inhalation) to CT50 (max-exhalation) as suggested by Kardar et al. and Li et al. [24, 25].
Only 8 of 10 patients met this criterion and thus used
for analysis. Table 1 lists the patient characteristics, the
tumor location, tumor size, and prescribed radiation
dose (Rx).
All patients had undergone 4D-CT scanning for treatment
planning purpose. The 4D-CT data sets were obtained using
a 16-detector row spiral CT scanner (Lightspeed 16; GE

Table 1 Patient Characteristics
Age (y/o)

Gender

Stage

Location

Motion (mm)

CTV Volume (cm3)

Rx (cGy/fx x fxs)

#1

87

F

IIIa

LML

4.6

349.4

200 × 33

#2

59

F

IV

LUL

1.4

265.1

200 × 33

#3

48

M

IIIa

LML

4.6

429.3

200 × 30

#4

65

M

IIIb

RUL

1.3

562.4

200 × 27

#5

67

F

III

RML

4.8

738.4

200 × 33

#6

79

F

IIIa

RML/RLL

5.2

265.9

200 × 30

#7

84

M

IV

LML

3.1

572.2

200 × 30

#8

61

F

IIIa

RML

2.7

435.6

200 × 30

y/o years old, RUL right upper lobe, RML right middle lobe, RLL, right lower lobe, LUL, left upper lobe, LML left middle lobe, LLL left lower lobe

Huang et al. Radiation Oncology (2018) 13:78

Page 3 of 10

Medical Systems, Milwaukee, WI, USA) in cine mode with
a 2.5-mm slice covering the entire chest. All received vocal
coaching with the Varian Real-time Position Management
system (Varian Medical Systems, Palo Alto, CA) to promote
regular respiration during 4D-CT acquisition. Image bins
corresponding to 10 phases of the respiratory cycle were
created. A medical physicist was present during each CT
scan to ensure that the patient’s breathing was not erratic.
4D-CT based ventilation imaging

The detail methodology of deriving ventilation map from
4D-CT was outlined by Yamamoto et al. [8]. In brief,
paired 4D-CT images at the peak-exhale and peak-inhale
phases were used for ventilation computation. The displacement vector field (DVF) was firstly generated using
deformable image registration (DIR). Then the Jacobian
determinant of DVF was created as a ventilation metric.
The regional ventilation, V (x, y, z), is given by:
V ðx; y; zÞ ¼
1 þ ∂ux ðx; y; zÞ
∂ux ðx; y; zÞ
∂ux ðx; y; zÞ
∂x
∂y
∂z
∂uy ðx; y; zÞ
1 þ ∂uy ðx; y; zÞ
∂uy ðx; y; zÞ
−1
∂x
∂y
∂z
∂uz ðx; y; zÞ
∂uz ðx; y; zÞ
1 þ ∂uz ðx; y; zÞ
∂x
∂y
∂z

determined for each voxel at the peak-exhale phase,
resulting in a 4D-CT ventilation map. Then the ventilation values outside the lung regions were zeroed out.
Two threshold values were identified for each case to
further divide the total lung into three equal volumes, as
low-, medium-, and high-functional lungs throughout
our report. An example of the functional lung of ventilation mapping procedure was shown in Fig. 1.
As the 4D-CT derived ventilation map could vary with
the DIR algorithms, the validity of this method has been
published in one of our previous works [26–28]. Briefly,
the DIR generated ventilation map was directly compared with that captured by hyperpolarized gas tagging
MRI on real patients. A large number (300–500) of uniformly distributed landmarks were identified throughout
the entire lung. A ground truth of DVF was obtained by
tracking the location of each tagged grid between the
exhalation and the inhalation images. The DVF generated
from seven DIR algorithms were compared to the ground
truth DVF included Velocity, MIM, Mirada, Elastix and 3
other in-house built algorithms from DIRART toolbox as
Double Force Demons, Improved Lucas-Kanade, and
Iterative Optical Flow. Among all algorithm, the Multipass B-spline based deformable image registration from
Velocity™ (Varian, Palo Alto, CA) gave the most reasonable result, which was thus used in this study.

ð1Þ
Anatomical and functional treatment planning

Where u(x,y,z) is the DVF of the voxel at location
(x,y,z) of a peak-exhale image to the corresponding location of a peak-inhale image. Regional ventilation was

Two treatment-planning scenarios were included in this
study: anatomical plans based on the constraints on the
total lung and functional plans using ventilation image-

Fig. 1 Schematic diagram for creating anatomical treatment plan and 4DCT ventilation image-based functional plan and quantifying impact of
functional planning. Step I-4DCT image acquisition; Step-II: to obtain the deformation vector fields (DVFs) using deformable image registration on
4DCT images; Step-III: Jacobian analysis of the DVFs to obtain regional ventilation map; Step-IV: segmentation of three functional lung regions
with equal volumes: low-functional (yellow), medium-functional (blue), and high-functional (orange) lung with ITV showing red. The obtained result is
used to create functional proton plans to further avoid high-functional lung regions
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guided information to avoid high-functioning lung. A total
of 5 plans were created for each individual patient to
quantify the impact of functional proton planning: (1) anatomical IMRT (aIMRT), (2) anatomical double scattering
proton treatment (aDSPT), (3) functional double scattering proton treatment (fDSPT), (4) anatomical intensity
modulated proton treatment (aIMPT), and (5) functional
intensity modulated proton treatment (fIMPT). Contouring and treatment planning were performed using the Varian Eclipse treatment planning system.
The target delineation and dosimetric constraints were
followed with RTOG 1308. The gross tumor volume
(GTV) was defined on the average CT image. The clinical target volume (CTV) was defined as GTV plus an 8mm margin for micro extension of the tumor. An internal target volume (ITV) was the union of the CTV
plus motions from all phases of respiration and edited
clinically based on pattern of tumor spreading and anatomic boundaries such as vertebral body, chest wall and
heart etc. The planning target volume (PTV), defined as
an expansion of the ITV by 5 mm, was used for IMRT
planning and all plans evaluation. Critical organs, including the heart, spinal cord, esophagus, and total
lungs, were contoured on the average CT image. The
spinal cord and esophagus were expanded by 5 mm for
planning purpose. The planned dose as calculated on
the average CT was defined as the 3D dose. All the plans
were designed to deliver 60–70 Gy (RBE: relative biological effective dose) with 2 Gy per fraction. The dose
constraints were given in Table 2.
For photon IMRT planning, the PTV was treated with
any combinations of coplanar or non-coplanar fields
shaped and modulated to deliver the specified dose while
restricting the dose to normal tissues. Beam weighting
and modulation were determined by inverse IMRT planning procedures. Photon plans were optimized to cover
the PTV. For proton DSPT treatment planning, a plan
with 2 or 3 fields was generated. The proton was modeled
to have a maximum energy of 250 MeV. The relative biologic effectiveness is taken to be 1.1. To compensate for
the perturbation of the proton dose distribution due to
the conversion uncertainty of CT numbers to proton
Table 2 Treatment planning goals and constraints
Structure

Constraints

PTV

No less than 95% coverage by prescription dose

Total Normal Lung

V20 ≤ 37%
V5 ≤ 60%
MLD (Mean Lung Dose) ≤ 20Gy

Spinal Cord

Dmax < 50 Gy

Heart

Dmean< 26 Gy

Esophagus

Dmean <34Gy
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stopping power, and the beam range uncertainty for
energy, variable scattering system thickness, and compensator density etc., the compensator was smeared using the
algorithms established by Moyers et al. [29]. If ITV was
used as the planning target, the distal and proximal margins in beam direction were determined by distal (proximal) m = 0.035 R + 3 mm, where R was the most distal
(proximal) water equivalent depth of the target volume. If
the PTV coverage was less than 95% coverage under the
ITV-based planning, then the PTV itself was used as the
planning target to ensure better coverage. In this situation,
smearing margins were considered to be zero [29]. To reduce hotspot, a 1-cm border-smoothing margin was further applied to the compensator. After the proton beams
were designed, dose was calculated on the average CT.
For IMPT treatment planning, the dose engine used proton pencil beams nominally defined in the 70 to 227 MeV
energy range. The spot size ranged from 3.2 mm (1 sigma)
at the isocenter in air at the maximum energy level to 7.
5 mm at the lowest energy level. The spot spacing was
fixed with 5 mm and ITV was used as the planning target.
Robust optimization with worst-case scenario, as first
introduce by Lomax et al. [30], was applied for each individual case. For any given beam arrangement, nine different dose scenarios were calculated simultaneously: the
nominal dose distribution (i.e., that with no consideration
of uncertainties) and dose distributions incorporating (1)
set-up uncertainties, obtained by shifting the isocenter of
the CT images by 5 mm along the anterior-posterior, leftright, and superior-inferior directions (yielding 6 dose distributions); and (2) range uncertainty, by scaling the relative stopping power ratios to water by 3.5% (yielding
additional 2 dose distributions). The worst-case dose distribution was then represented by the minimum of the 9
doses in each voxel in the ITV and the maximum of the 9
doses in each voxel outside the ITV. A difference of 5%
between the worst-case dose distribution and the nominal
dose was considered as acceptable. If the plan was found
to be not robust (quantified by a > 5% difference), then the
plans were re-optimized. The treatment plan was ultimately deemed acceptable if 95% of the PTV was covered
by the prescription dose.
For all the cases, the anatomically constrained plans
were generated blind of pulmonary ventilation information, basically treating the lung as a whole. The functionally constrained plans were generated with additional
constraints to further reduce the dose to the high functioning lung regions. Functional DSPT was achieved by
changing the gantry angles to avoid critical OARs and
highly functioning lung regions or by smoothing the
compensators. Functional IMPT was generated with
additional constraints to reduce the V5 and V20 of the
identified functional regions. In order to allow for a direct comparison, the number of beams and beam angels
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were kept identical for aDSPT vs. aIMPT plans. All plans
were normalized so that the D95 of the PTV equaled the
prescription dose. Also the hotspot inside the PTV was
limited to 115% of the prescription dose.
Statistical analysis

Statistical analyses were performed to quantify the impact
of proton treatment vs. photon treatment and functional
planning vs. anatomical planning. The percentage of lung
volume receiving > 5 Gy, and > 20 Gy were calculated for
the functional lung and total lung. Regarding the other
critical structures, the maximum dose (Dmax) delivered
to the spinal cord, the mean dose (Dmean) to esophagus,
the mean dose to the heart were also quantified.

Results
Comparison of all treatment plans for an example patient

Figure 2 shows the isodose distribution of an example
patient. As there was minimal exit dose for proton treatment, all proton plans showed clear sparing of the contralateral lung compared to the IMRT plans. In addition,
functional IMPT planning spared the high-functioning lung
further compared with anatomical planning. In particular,
the intermediate dose areas (2000 cGy – 5000 cGy) were
distorted toward to areas with less high-functioning lung.
Functional DSPT planning showed considerable distortions
of the isodose curves around the PTV compared with anatomical DSPT but the difference was not significant. The
total lung volumes receiving over 20 Gy (V20) was comparable between IMRT (38.4%) and DSPT (35.5% for aDSPT,
35.4% for fDSPT) but reduced to 24.3% (25.2%) with aIMPT

a

b

c

(fIMPT) treatment for this example case. The total lung receiving 5Gy (V5) were significantly reduced from 78.9% for
IMRT to 44.9% of aDSPT and 40.1% with aIMPT. The
high-functioning lung receiving 5Gy was reduced from 80.
2% (IMRT) to 47.6% with aIMPT, and further to 43.3% with
functional IMPT. The high-functioning lung V20 was 41.
6% from IMRT, reduced to 37.7% for aIMPT and further to
34.6% for fIMPT. In addition, functional planning did not
result in increases in heart dose. The mean dose of esophagus increased slightly from 9.6 Gy to 10.7 Gy from aIMPT
to fIMPT, but remained unchanged as 0.8 Gy for both anatomical and functional DSPT planning. The cord dose was
37.1 Gy for IMRT, reduced with proton treatment to 15.
8 Gy for aDSPT and remained unchanged with fDSPT. Although with functional IMPT planning, the cord max dose
increased from 28.1 Gy (aIMPT) to 31.5Gy (fIMPT), it still
met the dose constraint (Dmax < 50Gy).
Comparison of all treatment plans for all patients

Only 2/8 IMRT plans were clinically acceptable. Since
most of the tumors were located mediastinum or middle
lobe, achieving acceptable low V5 was the limiting factor
for most of the IMRT plans. The dosimetric metrics for
doses to critical structures are shown in Fig. 3. Both DSPT
and IMPT plans showed superior dose advantages to
photon IMRTs in sparing low dose regions of the total
lung. The functional planning in IMPT delivery, can further reduce the low dose in high-functioning lung without
degrading the PTV dosimetric coverages, compared to
anatomical proton planning. The median reductions in
the percentage of volume irradiated with > 5 Gy, and >

d

e

Fig. 2 Isodose distributions of an example patient showing multiple slices, from (a) IMRT, (b) anatomical double scattering proton treatment (aDSPT), (c)
functional double scattering proton treatment (fDSPT), (d) anatomical intensity modulated proton treatment (aIMPT), (c) functional intensity modulated
proton treatment (fIMPT) plans. The PTV is highlighted in red and high-functional lung regions are in orange
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a

b

c

d

e

f

g

h

i

Fig. 3 The box plot of dosimetric metrics across IMRT, anatomical DSPT, functional DSPT, anatomical IMPT and functional IMPT, (a) high functioning
lung V5, (b) high functioning lung V20, (c) high functioning lung mean lung dose (MLD), (d) total lung V5, (e) total lung V20, (f) total lung mean lung
dose (MLD), (g) heart mean dose, (h) esophagus mean dose, (i) cord max dose, respectively

20 Gy in high-functioning lung were 32.5% [15.4%–77.6%]
and 5.2% [− 3.9% -15.6%] for anatomical IMPT plans, and
further to 36.8% [21.0%–80.5%] and 7.2% [− 1.5%–17.6%]
for functional IMPT plans compared to IMRT. Although
the doses to several other critical organs might increase
during functional planning, the necessary constraints were
all met. For double scattering technique, the V20 of the
total lung is not necessarily lower but V5 was much lower
with median of 21.6% [6.6%–42.6%] reduction when compared to IMRT. The functional DSPT only showed marginal decrease in both high-functioning lung V5 and highfunctioning lung V20 compared to anatomical plans.

Discussion
In this study, we evaluated the impact of accounting
spatial heterogeneity in lung function using 4D-CT based

ventilation imaging for guided proton treatment to further
avoid high-functioning lung. Our results demonstrate that
functional proton planning, especially in intensity modulated spot-scanning delivery technique, can further reduce
the low-dose in high-functional lung regions compared to
anatomical proton planning. Although the doses to several
other critical organs might increase during functional
planning, the necessary constraints were all met. The
study presented here demonstrated the potentials of proton treatment in lowering the dose to the normal lung
and, for the first time demonstrated the benefit of using
4D-CT ventilation imaging to guide the proton treatment
to further sparing high-functional regions.
Current RT planning aimed at limiting lung toxicity
assumes a uniform response to radiation and fails to take
account of spatial and temporal pattern. Actually, different
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sections of lung could have different levels of pulmonary
functions [4]. Decreasing the radiation dose to functional
lung areas and directing the rays to the parts with perfusion/ventilation defects may help to protect highly functional regions and thus reduce the incidence and
seriousness of radiation pneumonitis [6–12]. Functional
imaging-guided radiotherapy with the purpose of local
boost or functional avoidance of normal organs is increasingly used in clinics. Lavrenkov et al. compared functional
IMRT planning and functional 3D-CRT planning using
single photon emission CT (SPECT) perfusion images
guided treatment and demonstrated that functional IMRT
planning led to a lower high functioning lung mean dose
than functional 3D-CRT planning [31]. Yamamoto et al.
demonstrated that 4D-CT ventilation imaging based functional IMRT and VMAT treatment planning, by changing
only one variable (i.e., absence/presence plan), led to significant reductions in the high-functioning lung dose [8].
However, previous work was mainly done with regular
photon treatment. The energy distribution of protons as
opposed to photon-based irradiation has theoretical advantages because of the Bragg peak of proton particles,
which can be exploited to reduce exposure of normal tissues to radiation, particularly at low doses. Under this
premise, emerging dosimetric and clinical studies are being undertaken to assess the role of proton radiotherapy
vs. photon and the associated clinical outcome [32–34].
Several studies have reported how NSCLC proton therapy
reduces the dose to the normal lung, heart, esophagus,
and spinal cord compared with IMRT, while delivering an
escalated dose [35]. Furthermore, a retrospective study
demonstrated that survival rates and high local control
rates can be potentially improved without enhancing
radiation-induced toxicities using proton therapy and concurrent chemotherapy [36]. To our best knowledge, it is
the first time that functional ventilation imaging derived
from 4D-CT was utilized to guide proton treatment. We
found functional proton treatment, in IMPT delivery, reduced the dose for high functioning lung without significantly increasing the doses to the other critical organs
compared to anatomic planning or at the expense of significantly degrading the target coverage. While the functional DSPT only showed marginal benefit in sparing low
dose to the high-functioning lung compared to anatomical
plans. But the proton treatment was in general giving less
low-dose to the total lung in terms of V5 compared to
IMRT treatment. Overall, these results might promote future dose-escalation studies with functional imaging
guided proton therapy for lung cancer treatment.
Before applying to future clinical studies, two major aspects need to be addressed. First is the validation of 4D-CT
derived ventilation imaging in depict patient pulmonary
function. There have been several studies attempted to
validate 4DCT-ventilation by comparing it against other

Page 7 of 10

ventilation imaging modalities such as nuclear medicine
ventilation-perfusion imaging [19], xenon-CT [14, 37], PET
[38], and MRI [39] or directly with pulmonary function test
[20]. The studies generally found good agreement on a
global level. Yet the regional physiologic accuracy has not
been validated in patients. In addition, temporal changes in
regional ventilation to a segment of lung previously
impaired by compression from a local tumor might occur
during the course of radiation treatment. A possible explanation of these changes is that the shrinkage of lung tumor
in response to radiation might increase the ventilation due
to reopening of the airways [40]. Nevertheless, additional
work is needed to validate the regional physiologic accuracy
of 4DCT derived ventilation imaging in real patients especially during the course of radiation treatment.
Secondly, proton radiotherapy in lung cancer raises
several issues. Among those, the most challenge one is
the tumor motion during treatment from patient’s
breathing. To take that into consideration, the target
volume was designed on 4D-CT based ITV with consideration of all respiratory motion. To further reduce the
chance of missing the target even when the target
moves, a relative large smearing margin as recommended by Moyers et al. [29] for highly mobile lung
tumors was utilized in double scattering proton therapy
(DSPT). This approach might slightly over treat the normal tissues behind the tumor when tumor moves out of
the field. However, it would make sure that whole tumor
be treated adequately no matter where it is located during the different breathing phases. On top of that, robust
optimization with worst case scenario was utilized in all
proton planning to evaluate the setup uncertainties and
range uncertainties. Regarding plan evaluation, using the
4D composite doses calculated with 4D-CT images and
deformable image registration (DIR) is a well-accepted
method of evaluating the actual delivered dose for DSPT
in the presence of respiratory motion [41]. It is our clinical practice to firstly evaluate the patient breathing motion based on the fluorescence and 4D scans. If the
breathing motion is less than 10 mm measured from
CT0 (end-of-inspiration) to CT50 (end-of-expiration),
then the patient can be recommended for DSPT treatment. And then the plan generated on the average CT is
transferred to the CT0 and CT50 using deformable
image registration. Only if the target coverage differences between these two extreme phases is less than 5%,
the plan is considered as robust. For the IMPT technique, the most concern comes from the interplay
effects between the moving beams and moving tissue.
The magnitude of the interplay effect with scanning proton beams has been reported in previous studies, and it
has been shown that proton dose could be impacted
enormously by the interplay effect for tumor motions
around or larger than 10 mm [42–47]. Kardar et al. and
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Li et al. introduced a 4D dynamic dose simulator and
further investigated the impact of motion pattern and
starting phases on the interplay effects [24, 25]. They observed situations in which motion more than 5 mm and
small tumor sizes led to relatively large uncertainties
caused by the interplay effect in a single fraction. In contrast, for some patients with motion less than 5 mm and
large tumor size treated with multi-fractionation, the
interplay effect was small. Moreover, a recent study by
Inoue et al. evaluated the impact of setup and range uncertainties, breathing motion, and interplay effects in
IMPT dose distributions [48]. Their results demonstrated
that in robust-optimized plans the dosimetric effects due
to geometric and radiologic variation had a limited impact
on target coverage, target dose homogeneity, and organat-risk dose parameters if treated with multi-fractionation.
As such, in our clinical practice, we selected patients with
breathing motion less than 5–7 mm but not small sizes of
lung tumors for IMPT. In addition, we compared the target coverage difference between the CT0 and CT50 using
a threshold of 5% as suggested by Kardar et al. and Li et
al. [24, 25]. Only those patients (8/10 in this study) met
the selection criterion were considered for IMPT treatment. Overall, further studies are needed to guarantee the
robust delivery of the proton treatment in 4D scenarios.
Nevertheless, as shown in our study, proton treatment
still reduced the doses to the normal tissues, especially
the low-dose exposure compared with IMRT. This may
have significant impact in reducing lung toxicity. Currently, there is insufficient outcome data to confirm the
correlation between functional lung dose-volume parameters and pulmonary toxicity endpoints, and further
studies are needed to determine if dosimetric reductions
to functional lung will translate into clinical benefits for
NSCLC patients. In addition, in a very recent review
paper by Ireland et al., that there may be patients with
specific types of functional defects and tumor volumes
and positions will benefit from the inclusion of functional data for normal lung dose reduction [49]. It will
be very interesting in the future to recruit more patients
to further identify the sub-cohort of the patients who
will benefit from not just proton treatment but also
functional data guided proton treatment.

Conclusions
In conclusion, this study demonstrated that incorporating 4DCT-based pulmonary ventilation information into
functional proton therapy is feasible. The functional proton plans, in IMPT delivery, were effective to furtherly
preserve high-functioning lung regions without degrading the PTV coverage. Although the doses to some critical organs might increase during functional planning,
the necessary constraints were all met.
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